Trial Profile

A Randomized, Placebo Controlled, Double-blind First-in-human Single Ascending Dose Study of LNA043 in Primary Osteoarthritis Patients Scheduled for Total Knee Replacement

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 17 Jan 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs LNA 043 (Primary)
Indications Osteoarthritis
Focus Adverse reactions; First in man
Sponsors Novartis Pharmaceuticals

Most Recent Events

01 Dec 2022 Results assessing role of LNA043 for cartilage regeneration in osteoarthritis, published in the Nature Medicine
02 Apr 2018 Status changed from recruiting to completed.
16 Oct 2017 Planned End Date changed from 3 Jan 2018 to 9 Jan 2018.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com